Coherus BioSciences Q4 Net Loss Narrows, Revenue Declines

MT Newswires Live03-10

Coherus BioSciences (CHRS) reported a Q4 non-GAAP net loss late Monday of $0.28 per diluted share, narrowing from a loss of $0.62 a year earlier.

Analysts surveyed by FactSet expected a loss of $0.19.

Total revenue for the quarter ended Dec. 31 was $54.1 million down from $91.5 million a year earlier.

Analysts polled by FactSet expected $44.1 million.

Chief Executive Officer Denny Lanfear said the company expects

cash position of about $250 million upon the completion of the UDENYCA divestiture and pay-off of its "significant" debt and royalty obligations.

"These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026," Lanfear said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2518783783?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-11 04:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2518783783","market":"sh","top_or_hot":-1,"title":"Coherus BioSciences Q4 Net Loss Narrows, Revenue Declines","media":"MT Newswires Live","content":"<html><body><p> Coherus BioSciences (CHRS) reported a Q4 non-GAAP net loss late Monday of $0.28 per diluted share, narrowing from a loss of $0.62 a year earlier.</p><p>Analysts surveyed by FactSet expected a loss of $0.19.</p><p>Total revenue for the quarter ended Dec. 31 was $54.1 million down from $91.5 million a year earlier.</p><p>Analysts polled by FactSet expected $44.1 million.</p><p>Chief Executive Officer Denny Lanfear said the company expects</p><p>cash position of about $250 million upon the completion of the UDENYCA divestiture and pay-off of its \"significant\" debt and royalty obligations.</p><p>\"These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026,\" Lanfear said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Coherus BioSciences Q4 Net Loss Narrows, Revenue Declines</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCoherus BioSciences Q4 Net Loss Narrows, Revenue Declines\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-11 04:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Coherus BioSciences (CHRS) reported a Q4 non-GAAP net loss late Monday of $0.28 per diluted share, narrowing from a loss of $0.62 a year earlier.</p><p>Analysts surveyed by FactSet expected a loss of $0.19.</p><p>Total revenue for the quarter ended Dec. 31 was $54.1 million down from $91.5 million a year earlier.</p><p>Analysts polled by FactSet expected $44.1 million.</p><p>Chief Executive Officer Denny Lanfear said the company expects</p><p>cash position of about $250 million upon the completion of the UDENYCA divestiture and pay-off of its \"significant\" debt and royalty obligations.</p><p>\"These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026,\" Lanfear said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CHRS","symbol_name":"Coherus Biosciences","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2518783783","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2518783783","pubTimestamp":1741639597,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Coherus BioSciences  reported a Q4 non-GAAP net loss late Monday of $0.28 per diluted share, narrowing from a loss of $0.62 a year earlier.Analysts surveyed by FactSet expected a loss of $0.19.Total revenue for the quarter ended Dec. 31 was $54.1 million down from $91.5 million a year earlier.Analysts polled by FactSet expected $44.1 million.Chief Executive Officer Denny Lanfear said the company expectscash position of about $250 million upon the completion of the UDENYCA divestiture and pay-off of its \"significant\" debt and royalty obligations.\"These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026,\" Lanfear said.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"CHRS":"Coherus Biosciences"},"translate_title":"Coherus BioSciences第四季度净亏损收窄，收入下降","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHRS":1},"content_text":"Coherus BioSciences (CHRS) reported a Q4 non-GAAP net loss late Monday of $0.28 per diluted share, narrowing from a loss of $0.62 a year earlier.Analysts surveyed by FactSet expected a loss of $0.19.Total revenue for the quarter ended Dec. 31 was $54.1 million down from $91.5 million a year earlier.Analysts polled by FactSet expected $44.1 million.Chief Executive Officer Denny Lanfear said the company expectscash position of about $250 million upon the completion of the UDENYCA divestiture and pay-off of its \"significant\" debt and royalty obligations.\"These efforts, combined with organizational streamlining, are expected to provide Coherus with a cash runway exceeding two years, funding the development pipeline through key data catalysts in 2025 and 2026,\" Lanfear said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2518783783"}